Asthma and COVID-19 (review)
https://doi.org/10.36604/1998-5029-2025-95-135-148
Abstract
An analysis and systematization of scientific literature on the combination of asthma and COVID-19 was conducted using the scientific databases PubMed/MEDLINE and eLIBRARY.RU. The data on the relationship between asthma and COVID-19 are shown to be contradictory. The mechanism of inflammation development and its characteristics in the new coronavirus infection are discussed. The significant role of natural killer (NK) cells and T-natural killer (T-NK) cells in the pathogenesis of the disease is emphasized. The importance of the type of inflammation in asthma in the risk of SARS-CoV-2 infection is concluded. Information on the dual nature of the data regarding the use of inhaled corticosteroids in the treatment of asthma in patients with COVID-19 is presented. The authors conclude that the results of current research do not allow a definitive conclusion to be drawn about a higher predisposition to SARS-CoV-2 infection or more severe COVID-19 in asthma patients, nor about the negative impact of COVID-19 on the course and control of asthma.
About the Authors
O. S. Kruglova
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State
Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Olga S. Kruglova, MD, Assistant of the Department of Hospital Therapy and Immunology with a Postgraduate Course
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
E. A. Sobko
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State
Medical University» of the Ministry of Healthcare of the Russian Federation; Regional State Budgetary Healthcare Institution «Regional Clinical Hospital»
Russian Federation
Russian Federation
Elena A. Sobko, MD, PhD, DSc (Med.), Professor of the Department of Hospital Therapy and Immunology with a Postgraduate Course; Head of the Allergology Department
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
3 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
I. V. Demko
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State
Medical University» of the Ministry of Healthcare of the Russian Federation; Regional State Budgetary Healthcare Institution «Regional Clinical Hospital»
Russian Federation
Russian Federation
Irina V. Demko, MD, PhD, DSc (Med.), Professor, Head of Department of Hospital Therapy and Immunology with Postgraduate Education Course; Head of Pulmonary Allergology Сenter
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
3 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
A. Yu. Kraposhina
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State
Medical University» of the Ministry of Healthcare of the Russian Federation; Regional State Budgetary Healthcare Institution «Regional Clinical Hospital»
Russian Federation
Russian Federation
Angelina Yu. Kraposhina, MD, PhD (Med.), Associate Professor, Associate Professor of Department of Hospital Therapy and Immunology with a Postgraduate Education Course; Pulmonologist of Department of Pulmonology
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
3 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
U. A. Khramova
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State
Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Uliya A. Khramova, student
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
S. A. Geyl'
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State
Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Sophiya A. Geyl', student
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
References
1. Svist P.G., Torchinsky N.V., Briko N.I., Avdeev S.N. [Prevalence of bronchial asthma and COPD in comorbidity with COVID-19]. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention 2024; 23(1):66–76 (in Russian). https://doi.org/10.31631/2073-3046-2024-23-1-66-76
2. Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan Y.Q., Akdis C.A., Gao Y-D. Clinical characteristics of patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7):1730–1741. https://doi.org/10.1111/all.14238
3. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054–1062. https://doi.org/10.1016/s01406736(20)30566-3
4. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Y. Xiong, Zhao Y., Li Y., Wang X., Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11):1061–1069. https://doi.org/10.1001/jama.2020.1585
5. Gaspar-Marques J., van Zeller M., Carreiro-Martins P., Chaves Loureiro C. Severe asthma in the era of COVID-19: a narrative review. Pulmonology 2022; 28(1): 34–43. https://doi.org/10.1016/j.pulmoe.2021.04.001
6. Adir Y., Saliba W., Beurnier A., Humbert M. Asthma and COVID-19: an update. Eur. Respir. Rev. 2021; 30(162):210152. https://doi.org/10.1183/16000617.0152-2021
7. Lipworth B., Chan R., Kuo C.R. Use of inhaled corticosteroids in asthma and coronavirus disease 2019: keep calm and carry on. Ann. Allergy Asthma Immunol. 2020; 125(5):503–504. https://doi.org/10.1016/j.anai.2020.06.026
8. Ramakrishnan S., Nicolau D.V. Jr, Langford B., Mahdi M., Jeffers H., Mwasuku C., Krassowska K., Fox R., Binnian I., Glover V., Bright S., Butler C., Cane J.L., Halner A., Matthews P.C., Donnelly L.E., Simpson J.L., Baker J.R., Fadai N.T., Peterson S., Bengtsson T., Barnes P.J., Russell R.E.K., Bafadhel M. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir. Med. 2021; 9(7):763–772. https://doi.org/10.1016/S2213-2600(21)00160-0
9. Lombardi C., Gani F., Berti A., Comberiati P., Peroni D., Cottini M. Asthma and COVID-19: a dangerous liaison? Asthma Res. Pract. 2021; 7(1):9. https://doi.org/10.1186/s40733-021-00075-z
10. Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J., Xiong W., Yang D., Chen R., Lu F., Lu Y., Liu X., Chen Y., Li X., Li Y., Summah H.D., Lin H., Yan J., Zhou M., Lu H., Qu J. COVID-19 with different severities: a multicenter study of clinical features. Am. J. Respir. Crit. Care Med. 2020; 201(11):1380–1388. https://doi.org/10.1164/rccm.202002-0445OC
11. Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., Ou C.Q., Li L., Chen P.Y., Sang L., Wang W., Li J.F., Li C.C., Ou L.M., Cheng B., Xiong S., Ni Z.Y., Xiang J., Hu Y., Liu L., Shan H., Lei C.L., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Cheng L.L., Ye F., Li S.Y., Zheng J.P., Zhang N.F., Zhong N.S., He J.X. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020; 55(5):2000547. https://doi.org/10.1183/13993003.00547-2020
12. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020; 94:91–95. https://doi.org/10.1016/j.ijid.2020.03.017
13. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W., the Northwell COVID19 Research Consortium, Barnaby D.P., Becker L.B., Chelico J.D., Cohen S.L., Cookingham J., Coppa K., Diefenbach M.A., Dominello A.J., Duer-Hefele J., Falzon L., Gitlin J., Hajizadeh N., Harvin T.G., Hirschwerk D.A., Kim E.J., Kozel Z.M., Marrast L.M., Mogavero J.N., Osorio G.A., Qiu M.,Zanos T.P. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323(20):2052–2059. https://doi.org/10.1001/jama.2020.6775
14. Williamson E.J., Walke A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H.I., MacKenna B., Tomlinson L., Douglas I.J., Rentsch C.T., Mathur R., Wong A.Y.S., Grieve R., Harrison D., Forbes H., Schultze A., Croker R., Parry J., Hester F., Harper S., Perera R., Evans S.J.W., Smeeth L., Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430– 436. https://doi.org/10.1038/s41586-020-2521-4
15. Sunjaya A.P., Allida S.M., Di Tanna G.L., Jenkins C.R. Asthma and COVID-19 risk: a systematic review and metaanalysis. Eur. Respir. J. 2022; 59(3): 2101209. https://doi.org/10.1183/13993003.01209-2021
16. Liu S., Zhi Y., Ying S. COVID-19 and asthma: reflection during the pandemic. Clin. Rev. Allergy Immunol. 2020; 59(3): 78–88. https://doi.org/10.1007/s12016-020-08797-3
17. Zhu Z., Hasegawa K., Ma B., Fujiogi M., Camargo Jr. C.A., Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. JACI 2020; 146(2):327–329.e.4. https://doi.org/10.1016/j.jaci.2020.06.001
18. Murphy T.R., Busse W., Holweg C.T.J., Rajput Y., Raimundo K., Meyer C.S., Seetasith A., Gupta S., Iqbal A., Kaner R.J. Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma. BMC Pulmonary Medicine 2022; 22(1):418. https://doi.org/10.1186/s12890-022-02230-5
19. Yang J.M., Koh H.Y., Moon S.Y., Yoo I.K., Ha E.K., You S., Kim S.Y., Yo D.K., Lee S.W. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. JACI 2020; 146(4):790–798. https://doi.org/10.1016/j.jaci.2020.08.008
20. Urbani F., Cometa M., Martelli C., Santoli F., Rana R., Ursitti A., Bonato M., Baraldo S., Contoli M., Papi A. Update on virus-induced asthma exacerbations. Expert Rev. Clin. Immunol. 2023; 19(10):1259–1272. https://doi.org/10.1080/1744666X.2023.2239504
21. Bolevich S.B., Bolevich S.S. Complex mechanism of COVID-19 development. Sechenov Medical Journal 2020; 11(2):50–61. https://doi.org/10.47093/2218-7332.2020.11.2.50-61
22. Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020; 14(2):185–192. https://doi/org/10.1007/s11684-020-0754-0
23. Song Z., Xu Y., Bao L., Zhang L., Yu P., Qu Y., Zhu H., Zhao W., Han Y., Qin C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019; 11(1):59. https://doi.org/10.3390/v11010059
24. Shulmeyster G.A., CheburkinYu.V., ChekmenevaYu.D., Edemskaya E.V., Bondarenko A.B., Postnov V.N., Korolev D.V. [Prototypes of SARS-CoV-2 virus “traps” based on enterosorbents]. Translyatsionnaya meditsina = Translational Medicine 2024; 11(1):28–44 (in Russian). https://doi.org/10.18705/2311-4495-2024-11-1-28-44
25. Chen Y., Lin J., Zhao Y., Ma X., YiH. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J. Zhejiang Univ. Sci. 2021; 22(8):609–632. https://doi.org/10.1631/jzus.B2000808
26. Aboudounya M.M., Holt M.R., Heads R. J. SARS-CoV-2 Spike S1 glycoprotein is a TLR4 agonist, upregulates ACE2 expression and induces pro-inflammatory M1 macrophage polarization. BioRxiv 2021. https://doi.org/10.1101/2021.08.11.455921
27. Wang K., Chen W., Zhang Z., Deng Y., Lian J.-Q., Du P., Wei D., Zhang Y., Sun X.-X., Gong L., Yang X., He L., Zhang L., Yang Z., Geng J.-J., Chen R., Zhang H., Wang B., Zhu Y.-M., Nan G., Jiang J.-L., Li L., Wu J., Lin P., Huang W., Xie L., Zheng Z.-H., Zhang K., Miao J.-L., Cui H.-Y., Huang M., Zhang J., Fu L., Yang X.-M., Zhao Z., Sun S., Gu H., Wang Z., Wang C.-F., Lu Y., Liu Y.-Y., Wang Q.-Y., Bian H., Zhu P., Chen Z.-N. 11CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020; 5(1):83. https://doi.org/10.1038/s41392020-00426-x
28. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
29. Sсherbak S.G., Vologzhanin D.A., Golota A.S., Kamilova T.A., Makarenko S.V. [Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications]. Klinicheskaya praktika = Journal of Clinical Practice 2022; 13(2):66–87 (in Russian). https://doi.org/10.17816/clinpract106239
30. Kaneko N., Kuo H.H., Boucau J., Farmer J.R., Allard-Chamard H., Mahajan V.S., Piechocka-Trocha A., Lefteri K., Osborn M., Bals J., Bartsch Y.C., Bonheur N., Caradonna T.M., Chevalier J., Chowdhury F., Diefenbach T.J., Einkauf K., Fallon J., Feldman J., Finn K.K., Garcia-Broncano P., Hartana C.A., Hauser B.M., Jiang C., Kaplonek P., Karpell M., Koscher E.C., Lian X., Liu H., Liu J., Ly N.L., Michell A.R., Rassadkina Y., Seiger K., Sessa L., Shin S., Singh N., Sun W., Sun X., Ticheli H.J., Waring M.T., Zhu A.L., Alter G., Li J.Z., Lingwood D., Schmidt A.G., Lichterfeld M., Walker B.D., Yu X.G., Padera R.F.Jr., Pillai S.; Massachusetts consortium on pathogen readiness specimen working group. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell 2020; 183(1):143–157.e13. https://doi.org/10.1016/j.cell.2020.08.025
31. Danilov S.M., Sadovnikova E., Scharenborg N., ParovichnikovaE.N.. Savchenko V.G., Adema G.J. Angiotensinconverting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Experimental Hematology 2003; 31(12):1301–1309. https://doi.org/10.1016/j.exphem.2003.08.018
32. Danilova G.A., Alexandrov V.G., Alexandrova N.P. [Effect of intravenous administration of the proinflammatory cytokine il-1β on the chemoreceptor control of respiration]. Patologicheskaya fiziologiya i eksperimental'naya terapiya = Pathological physiology and experimental therapy 2023; 67(1):63–70 (in Russian). https://doi.org/10.25557/00312991.2023.01.63-70
33. Frey A., Lunding L.P., Ehlers J.C., Weckmann M., Zissler U.M., Wegmann M. More than just a barrier: the immune functions of the airway epithelium in asthma pathogenesis. Front. Immunol. 2020; 11:761. https://doi.org/10.3389/fimmu.2020.00761
34. Schwane V., Huynh-Tran V.H., Vollmers S., Yakup V.M., Sauter J., Schmidt A.H., Peine S., Altfeld M., Richert L., Körner C. Distinct signatures in the receptor repertoire discriminate CD56bright and CD56dim Natural Killer cells. Front. Immunol. 2020; 11:568927. https://doi.org/10.3389/fimmu.2020.568927
35. Walzer T., Dalod M., Robbins S. H., Zitvogel L., Vivier E. Natural-killer cells and dendritic cells: “L'union fait la force”. Blood 2005; 106(7):2252–2258. https://doi.org/10.1182/blood-2005-03-1154
36. Rea I.M., Gibson D.S., McGilligan V., McNerlan S.E., Alexander H.D., Ross O.A. Age and age-related diseases: role of inflammation triggers and cytokines. Front. Immunol. 2018; 9:586. https://doi.org/10.3389/fimmu.2018.01869
37. Fasbender F., Widera A., Hengstler J.G., Watzl C. Natural killer cells and liver fibrosis. Front. Immunol. 2016; 7: 19. https://doi.org/10.3389/fimmu.2016.00019
38. Orr M.T, Lanier L.L. Natural killer cell education and tolerance. Cell 2010; 142(6):847–856. https://doi.org/10.1016/j.cell.2010.08.031
39. Cassidy S.A., Cheent K.S., Khakoo S.I. Effects of peptide on NK cell-mediated MHC I recognition. Front. Immunol. 2014; 5:133. https://doi.org/10.3389/fimmu.2014.00133
40. Yewdell J.W., Bennink J.R. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu. Rev. Cell Dev. Biol. 1999; 15:579–606. https://doi.org/10.1146/annurev.cellbio.15.1.579
41. Abakushina E.V., Kuzmina E.G., Kovalenko E.I. [The main characteristics of human natural killer cells]. Immunologiya = Immunology 2012; 33(4):220–224 (in Russian).
42. Qin C., Zhou l., Hu Z., Zhang S., Yang Sh., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020; 71(15):762– 768. https://doi.org/10.1093/cid/ciaa248
43. Michel T., Poli A., Cuapio A., Briquemont B., Iserentant G., Ollert M., Zimmer J. Human CD56brightNK cells: an update. J. Immunol. 2016; 196(7):2923–2931. https://doi.org/10.4049/jimmunol.1502570
44. Kumar A., Suryadevara N., Hill T.M., Bezbradica J.S., Kaer L.V., Joyce S. Natural killer T cells: an ecological evolutionary developmental biology perspective. Front. Immunol. 2017; 8:1858. https://doi.org/10.3389/fimmu.2017.01858
45. Liu M., Liang S., Zhang C. NK Cells in autoimmune diseases: protective or pathogenic? Front. Immunol. 2021; 12:624687. https://doi.org/10.3389/fimmu.2021.624687
46. Ghasemzadeh M., Ghasemzadeh A., Hosseini E. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. Hum. Immunol. 2022; 83(1):86–98. https://doi.org/10.1016/j.humimm.2021.09.004
47. O'Brien T.F., Bao K., Dell'Aringa M., Ang W.X.G., Abraham S., Reinhardt R.L. Cytokine expression by invariant natural killer T cells is tightly regulated throughout development and settings of type-2 inflammation. Mucosal Immunol. 2016; 9(3):597–609. https://doi.org/10.1038/mi.2015.78
48. Lepretre F., Gras D., Chanez P., Duez C. Natural killer cells in the lung: potential role in asthma and virus-induced exacerbation? Eur. Respir. Rev. 2023; 32(169):230036. https://doi.org/10.1183/16000617.0036-2023
49. Gupta S., Hayek S.S., Wang W.,Chan L., Mathews K.S., Melamed M.L., Brenner S.K., Leonberg-Yoo A., Schenck E.J., Radbel J., Reiser J., Bansal A., Srivastava A., Zhou Y., Sutherland A., Green A., Shehata A.M., Goyal N., Vijayan A., Velez J.C.Q., Shaefi S., Parikh C.R., Arunthamakun J., Athavale A.M., Friedman A.N., Short S.A.P., Kibbelaar Z.A., Omar S.A., Admon A.J., Donnelly J.P., Gershengorn H.B., Hernán M.A., Semler M.W., Leaf D.E.; STOP-COVID investigators. Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US. JAMA 2020; 180(11):1436–1447. https://doi.org/10.1001/jamainternmed.2020.3596
50. Tabassum T., Rahman A., Araf Y., Ullah A., Hosen M.J. Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges. Beni- Suef Univ. J. Basic. Appl. Sci. 2022; 11(1):20. https://doi.org/10.1186/s43088-022-00204-4
51. Wilk A.J., Rustagi A., Zhao N.Q., Roque J., Martínez-Colón G.J., McKechnie J.L., Ivison G.T., Ranganath T., Vergara R., Hollis T., Simpson L.J., Grant P., Subramanian A., Rogers A.J., Blish C.A. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 2020; 26(7):1070–1076. https://doi.org/10.1038/s41591020-0944-y
52. Zhuang C., Zhong Y., Zhao Y. Effect of deacetylation degree on properties of chitosan films using electrostatic spraying technique. Food Control. 2018; 97: 25–31. https://doi.org/10.1016/j.foodcont.2018.10.014
53. Lee S., Son K., Han C., Jung J., Park S. Impact of comorbid asthma on severity of coronavirus disease (COVID- 19). Sci. Rep. 2020; 10(1):21805. https://doi.org/10.1038/s41598-020-77791-8
54. Jackson D.J., Busse W.W., Bacharier L.B., Kattan M., O’Connor G.T., Wood R.A., Visness C.M., Durham S.R., Larson D., Esnault S., Ober C. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J. Allergy Clin. Immunol. 2020; 146(1):203–206. https://doi.org/10.1016/j.jaci.2020.04.009
55. Cauchois R., Pietri L., Dalmas J.-B., Koubi M., Capron T., Cassir N., Potere N., Polidoro I., Jean R., Jarrot P.-A., Andre B., Veit V., Carvelli J., Pauly V., Chanez P., Papazian L., Kaplanski G. Eosinopenia as predictor of poor outcome in hospitalized COVID-19 adult patients from waves 1 and 2 of 2020 Pandemic. Microorganisms 2022; 10(12):2423. https://doi.org/10.3390/microorganisms10122423
56. Lombardi C., Bagnasco D., Passalacqua G. COVID-19, eosinophils, and biologicals for severe asthma. Front. Allergy 2022; 3:859376. https://doi.org/10.3389/falgy.2022.859376
57. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm IgE’s central role in allergic inflammation. J. Allergy Clin. Immunol. 2005; 115(3):459–465. https://doi.org/10.1016/j.jaci.2004.11.053
58. Chałubiński M., Gajewski A., Kowalski M. The relationship between human coronaviruses, asthma and allergy – an unresolved dilemma. Clin. Exp. Allergy 2020; 50(10):1122–1126. https://doi.org/10.1111/cea.13718
59. Akbari O., Faul J., Hoyte E., Berry G., Wahlström J., Kronenberg M., DeKruyff R.H., Umetsu D.T. CD4+ invariant T-cell–receptor+ natural killer T cells in bronchial asthma. N. Engl. J. Med. 2006; 354(110):1117–1129. https://doi.org/10.1056/NEJMoa053614
60. Beurnier A., Jutant E., Jevnikar M., Boucly A., Pichon J., Preda M., Frank M., Laurent J., Richard C., Monnet X., Duranteau J., Harrois A., Chaumais M.-C., Bellin M.-F., Noël N., Bulifon S., Jaïs X., Parent F., Seferian A., Savale L., Sitbon O., Montani D., Humbert M. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalization. Eur. Respir. J. 2020; 56(5):2001875. https://doi.org/10.1183/13993003.01875-2020
61. Bloom C.I., Drake T.M., Docherty A.B., Lipworth B.J., Johnston S.L., Nguyen-Van-Tam J.S., Carson G., Dunning J., Harrison E.M., Baillie J.K., Semple M.G., Cullinan P., Openshaw P.J.M.; ISARIC investigators. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir. Med. 2021; 9(7):699–711. https://doi.org/10.1016/S2213-2600(21)00013-8
62. Morais-Almeida M., Aguiar R., Martin B., Ansotegui I.J., Ebisawa M., Arruda L.K., Caminati M., Canonica G.W., Carr T., Chupp G., Corren J., Dávila I., Park H.S., Hanania N.A., Rosenwasser L., Sánchez-Borges M., Virchow J.C., Yáñez A., Bernstein J.A., Caraballo L., Chang Y.S., Chikhladze M., Fiocchi A., González-Diaz S.N., Tanno L.K., Levin M., Ortega-Martell J.A., Passalacqua G., Peden D.B., Rouadi P.W., Sublett J.L., Wong G.W.K., Bleecker E.R. COVID19, asthma, and biological therapies: what we need to know. World Allergy Organ. J. 2020; 13(5):100126. https://doi.org/10.1016/j.waojou.2020.100126
63. Abrams E.M, Jong G.W., Yang C.L. Asthma and COVID-19. CMAJ 2020; 192(200):E551. https://doi.org/10.1503/cmaj.200617
64. Levina J.G., Namazova-Baranova L.S., Vishneva E.A., Efendieva K.Y., Alekseeva A.A., Kalugina V.G., Arimova P.S., Volkov K.S., Denisova A.R. [Asthma activity and respiratory morbidity in children during the covid-19 pandemic: results of a retrospective comparative observational study]. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences 2020; 75(5S):455–464 (in Russian). https://doi.org/10.15690/vramn1448
65. Starshinova A., Borozinets A., Kulpina A., Sereda V., Rubinstein A., Kudryavtsev I., Kudlay D. Bronchial asthma and COVID-19: etiology, pathological triggers, and therapeutic considerations. Pathophysiology 2024; 31(2):269–287. https://doi.org/10.3390/pathophysiology31020020
66. O’Beirne S.L., Salit J., Kaner R.J., Crystal R.G., Strulovici-Barel Y. Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids. Respir. Res. 2021; 22(1):200 https://doi.org/10.1186/s12931021-01782-0
67. Yu L.-M., Bafadhel M., Dorward J., Hayward G., Saville B.R., Gbinigie O., Hecke O.V., Ogburn E., Evans P.H., Thomas N.P.B., Patel M.G., Richards D., Berry N., Detry M.A., Saunders C., Fitzgerald M., Harris V., Shanyinde M., de Lusignan S., Andersson M.I., Barnes P.J., Russell R.E.K., Nicolau Jr D.V., Ramakrishnan S., Hobbs F.D.R., Butler C.C., N.P.B. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 398(10303):843–855. https://doi.org/10.1016/s0140-6736(21)01744-x
68. Bull-Otterson L., Baca S., Saydah S., Boehmer T.K., Adjei S., Gray S., Harris A.M. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years – United States, March 2020 - November 2021. MMWR 2022; 71(21):713–717. https://doi.org/10.15585/mmwr.mm7121e1
69. Mizrahi B., Sudry T., Flaks-Manov N., Yehezkelli Y., Kalkstein N., Akiva P., Ekka-Zohar A., David S.S.B., Lerner U., Bivas-Benita M., Greenfeld S. Long COVID outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 2023; 380:e072529. https://doi.org/10.1136/bmj-2022-072529
70. Ma-Van-de V.D., Zaitsev D.N., Filev A.P., Mukha N.V., Ratsina E.V., Vasilenko P.V., Vasilenko E.A., Fetisova N.V. [Clinical and laboratory markers of severity of the new coronavirus infection (COVID - 19)]. Sibirskoye meditsinskoye obozreniye = Siberian Medical Review 2022; 3-135:40–48 (in Russian). https://doi.org/10.20333/25000136-2022-3-40-48
71. Agafonova T.Yu., Elovikova N.N., Fadeeva A.N., Igisheva D.A., Reshetnyak V.O., Yudina A.A. [Post-COVID syndrome in women of different ages with laboratory-proven and non-confirmed COVID-19]. Meditsinskiy alfavit = Medical alphabet 2023; 23:24–29 (in Russian). https://doi.org/10.33667/2078-5631-2023-23-24-29
72. Philip K.E.J., Buttery S., Williams P., Vijayakumar B., Tonkin J., Cumella A., Renwick L., Ogden L., Quint J.K., Johnston S.L., Polkey M.I., Hopkinson N.S. Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey. BMJ Open Resp. Res. 2022; 9:e001056. https://doi.org/10.1136/bmjresp-2021-001056
Review
For citations:
Kruglova O.S., Sobko E.A., Demko I.V., Kraposhina A.Yu., Khramova U.A., Geyl' S.A. Asthma and COVID-19 (review). Bulletin Physiology and Pathology of Respiration. 2025;(95):135-148. (In Russ.) https://doi.org/10.36604/1998-5029-2025-95-135-148
Views:
180
Email this article 